Allon Therapeutics announces davunetide receives FDA Fast Track Status for treatment of Progressive Supranuclear Palsy
06-Apr-2010 -
Allon Therapeutics Inc. announced that its lead neuroprotective drug candidate, davunetide, has been granted Fast Track status from the United States Food and Drug Administration (FDA) for the treatment of Progressive Supranuclear Palsy (PSP), a rapidly-progressing and fatal degenerative brain ...
brain diseases
Fast Track status
food
+2